Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Gurgaon, India-based Ranbaxy Laboratories has delayed plans to spin off its research unit until the second half of the year, but noted during a Jan. 17 press conference that it had settled a key lawsuit over Flomax (tamsulosin) and expanded a development deal with GlaxoSmithKline that will secure earnings momentum
You may also be interested in...
Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study
Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010
Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study
Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010
Ranbaxy To Announce New Drug Development Tie-Up In May
NEW DELHI - India's top generic drug firm Ranbaxy Laboratories expects to announce a new tie up with a large multinational drug firm in May to develop new chemical entities at its recently spun-off Life Science Research unit similar to a current deal with GlaxoSmithKline inked in 2003 and expanded last year, the company's chief executive said